ClinicalTrials.gg
CompletedNCT07171619Updated May 8, 2026

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

A Phase 1 interventional study of Nirogacestat and Nirogacestat and Famotidine in Healthy, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants

Read the detailed description

This is a phase 1, single-center, single-sequence crossover study to compare the PK, safety, and tolerability of nirogacestat alone or coadministered with famotidine or rabeprazole. This study will consist of 3 periods: Period 1 Nirogacestat Alone (Reference), Period 2 Nirogacestat and Famotidine (Test), and Period 3 Nirogacestat and Rabeprazole (Test).

There will be a screening period of up to 28 days prior to Day 1. Eligible participants will be enrolled in the study and will complete a 21-day Treatment Period. A follow-up (FU) telephone call will be performed approximately 26 days after discharge from the clinical research unit (CRU) on Day 47 (+2 days).

During screening, participants will sign the informed consent form (ICF) prior to any study procedures being performed. Participants must satisfy all the inclusion and exclusion criteria to be eligible for study participation. Participants will be admitted to the CRU on Day -1 for check-in procedures and eligibility confirmation. Participants will remain domiciled at the CRU until Day 21 after the last PK sample is collected and safety evaluations are completed.

Participants will receive a single 150 mg dose of nirogacestat in the morning of Day 1 following an overnight fast of at least 10 hours once eligibility is confirmed. Study treatment (nirogacestat) will be administered by mouth (PO) followed by 240 mL of water; otherwise, additional fluids will be restricted from 1 hour predose until 2 hours postdose. A mouth check will be done to ensure the study treatment has been consumed. Participants will continue to fast for approximately 4 hours after administration of study treatment.

On Day 6, participants will be administered a single 150 mg dose of nirogacestat in the morning after an overnight fast of at least 10 hours. Study treatment (nirogacestat) will be administered PO followed by 240 mL of water; otherwise, additional fluids will be restricted from 1 hour predose until 2 hours postdose. Two hours after the administration of nirogacestat, participants will be administered 40 mg of famotidine PO followed by 240 mL of water; additional fluids will be restricted until 2 hours post dose of famotidine and participants will continue to fast for approximately 2 hours after administration of famotidine.

Beginning in the evening of Day 10 through Day 16, participants will be administered a single dose of rabeprazole each evening. On Day 17, following an overnight fast of at least 10 hours, participants will receive a single dose of nirogacestat in the morning. Study treatment will be administered PO followed by 240 mL of water; additional fluids will be restricted from 1 hour predose until 2 hours postdose; otherwise, participants will continue to fast for approximately 4 hours after administration of nirogacestat.

Participants will remain domiciled at the CRU until all safety evaluations are completed on Day 21.

Participants will complete a FU telephone visit on Day 47 (+2 days) for review of AEs/SAEs and concomitant medications.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant understands the study procedures, is willing to comply with all study requirements and restrictions, and agrees to participate in the study by providing written as described in Appendix 1 of the protocol, prior to any study-related procedures being performed.
  2. Participant is a male (assigned at birth) between 18 and 55 years of age (inclusive) at the time of informed consent.
  3. Participant has a (BMI) ≥18.0 kg/m2 and ≤32.0 kg/m2 (inclusive) at Screening and a total body weight >50 kg.
  4. Participant is considered to be medically healthy, as determined by a responsible and experienced investigator, based on a clinical evaluation (including medical history, physical examination, clinical laboratory tests, vital sign measurements, and a 12-lead performed, and the results of clinical chemistry, hematology, coagulation, and urinalysis carried out at Screening and Day -1.
  5. Participant has (ALT), aspartate aminotransferase (AST), and total levels \<1.5 × the (ULN) at Screening and at Day -1.
  6. Participant has normal renal function ( ≥90 mL/min) as evidenced by normal estimated (eGFR) measured by the CKD-EPI equation.
  7. Participant agrees to the following during the treatment periods and for at least 7 days after the last dose of study treatment:

    1. Refrain from donating or preserving sperm; PLUS either
    2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

      OR

    3. Must agree to use a male condom when having sexual intercourse with women of (WOCBP). An additional form of should also be used by the female partner if she is of childbearing potential.
  8. Has sufficiently good venous access in at least one arm to confidently enable serial blood sampling.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history or presence of oncologic, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, ocular, endocrine, immunologic, dermatologic, musculoskeletal, neurologic, psychiatric, or other disease or condition or laboratory test abnormality that in the investigator's judgment poses a significant risk to the safety of the participant or the achievement of study objectives.
  2. Participant has a history or presence of any condition possibly affecting drug absorption (e.g., gastrectomy).
  3. Participant has a medical history or abnormal findings at Screening or Day -1 that the investigator judges may put at risk achieving the objectives of the study or protecting the safety of the participant.
  4. Participant has an acute illness with symptom or treatment that has started or persisted within 14 days prior to study treatment administration unless mild in severity and enrollment is approved by both investigator and sponsor's medical monitor.
  5. Participant has tested positive for active Helicobacter pylori (H. pylori) infection.
  6. Participant has tested positive for virus (HBV), virus (HCV), or (HIV) or has a infection.
  7. Participant has blood pressure (BP) that is ≥140 mmHg systolic or 90 mmHg diastolic following at least 5 minutes of rest in the supine position at Screening and Day -1. Additionally, BP that is \<90 mmHg systolic or 45 mmHg diastolic following at least 5 minutes of rest at Screening and Day -1.
  8. Participant has heart rate (HR) that is \<40 bpm or >100 bpm after resting in a supine position for 5 minutes at Screening and Day -1.
  9. Participant has averaged corrected using Fridericia formula (QTcF) results from valid triplicate ECGs >450 msec at Screening and Day -1.
  10. Participant has family history of long QT syndrome or of unexplained sudden death or drowning in a first-degree relative under age 50.
  11. Participant has an waveform abnormality that interferes with QT/QTc interval measurement or interpretation. A participant with mild sinus arrhythmia or sparse isolated premature ventricular contractions (PVC) is eligible at the investigator's discretion.
  12. Participant has a positive alcohol breath test, positive cotinine test, or other positive drug screen test at Screening or Day -1.
  13. Participant has a positive nasopharyngeal rapid antigen test for SARS-CoV-2 on Day -1 or has had any known close contact with a person who tested positive for SARS-CoV-2 or with a COVID-19 patient within 2 weeks prior to admission.
  14. Participant has received any vaccine within 14 days prior to the first dose of study treatment administration on Day 1.
  15. Participant has received any inhibitors or inducers within 21 days or 5 half-lives (whichever is longer) prior to Day 1.
  16. Participant has had concurrent use of long-acting gastric acid-reducing agents within 21 days of Day 1, including H2 blockers and PPIs, including over-the-counter agents.
  17. Participant has received any prescription or non-prescription drugs (including vitamins and dietary or herbal supplements), within 3 weeks or 5 half-lives, if known (whichever is longer) prior to study treatment administration on Day 1.
  18. Participant has received an product within 30 days or 5 times the half-lives, if known, of any drug used in the prior study (whichever is longer), or exposure to more than 3 new investigational agents within 12 months prior to study treatment administration on Day 1.
  19. Participant has a known or intolerance to any of the study treatments, or thereof, or a history of drug or other allergy that, in the opinion of the investigator or sponsor medical monitor, contraindicates their participation.
  20. Participant has a history of excessive intake of alcohol, defined as an average daily intake of >3 units, or an average weekly intake of >14 units (1 unit is equivalent to 1 can or bottle [250 mL] of beer, or 1 measure [35 mL] of spirits, or 1 glass [100 mL] of wine) in the last 6 months prior to Screening.
  21. Participant has a history of illicit drug abuse within the past 2 years prior to Screening.
  22. Participant has consumed red wine or any fruit juices (including but not limited to Seville oranges, grapefruit, grapefruit juice, star fruit, star fruit juice, pomelos, exotic citrus fruits, grapefruit hybrids) within 72 hours of Day -1, as outlined in Section 5.3.1.
  23. Participant has used caffeine or other xanthine-containing products (e.g., coffee, black tea, green tea, colas, cacao, guarana, guayusa, yerba mate) within 24 hours of Screening and Day -1.
  24. Participant regularly consumes excessive amounts (defined as >5 cups per day) of caffeine, xanthine-containing products, or energy drinks as judged by the investigator.
  25. Participant has used tobacco- or nicotine-containing products within 2 months prior to Screening.
  26. Participant has donated blood or had a loss of >450 mL of blood within 60 days or donation of plasma within 7 days prior to Screening.
  27. Participant has received blood products within the 60 days prior to Screening.
  28. Participant is unwilling to avoid strenuous or unaccustomed activity, sunbathing, or contact sports within 48 hours prior to admission to the CRU and until discharge from the CRU.
  29. Participant is deemed unsuitable for this study in the opinion of the investigator for any additional reason, condition, or prior therapy.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Period 1 - Nirogacestat Dose (Reference)

    Nirogacestat will be administered, after at least a 10-hour fast, in the morning on Day 1, Day 6, and Day 17

    Drug: Nirogacestat

  • Active comparator
    Period 2 - Nirogacestat and Famotidine (Test)

    Famotidine will be administered as an oral tablet 2 hours after the administration of nirogacestat on Day 6.

    Drug: Nirogacestat and Famotidine

  • Active comparator
    Period 3 Nirogacestat and Rabeprazole (Test)

    Rabeprazole will be administered as an oral tablet in the evenings on Day 10 through Day 16.

    Drug: Nirogacestat and Rabeprazole

Interventions

  • oral dose of 150 mg nirogacestat

    Also known as: PF-03084014- GS (gamma secretase) inhibitor

  • DrugNirogacestat and Famotidine

    Drug pages: Nirogacestat · Famotidine

    oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine

    Also known as: Histamine H2-Receptor Antagonist (H2 Blocker)

  • DrugNirogacestat and Rabeprazole

    Drug pages: Nirogacestat · Rabeprazole

    oral dose of 150 mg nirogacestat and oral dose of 20 mg rabeprazole

    Also known as: Proton Pump Inhibitor (PPI)

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to infinity of nirogacestat.

    Serum AUCinf of nirogacestat.

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  2. Maximum serum concentration (Cmax) of nirogacestat.

    Serum Cmax of nirogacestat.

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  3. Effect of a single 2-hour staggered dose of famotidine on the PK AUCinf of nirogacestat

    Serum AUCinf of nirogacestat.

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  4. Effect of a single 2-hour staggered dose of famotidine on the PK Cmax of nirogacestat

    Serum Cmax of nirogacestat.

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

Secondary outcomes

  1. Determine the effect of rabeprazole or famotidine on nirogacestat PK (AUClast) Area under the concentration-time curve from zero to the time last quantifiable concentration

    Serum AUClast

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  2. Determine the effect of rabeprazole or famotidine on nirogacestat PK (Tmax) time of maximum concentration

    Serum Tmax

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  3. Determine the effect of rabeprazole or famotidine on nirogacestat PK (T1/2) Terminal elimination half-life

    Serum T1/2

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  4. Determine the effect of rabeprazole or famotidine on nirogacestat PK (CL/F) apparent clearance after oral dose

    Serum CL/F

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  5. Determine the effect of rabeprazole or famotidine on nirogacestat PK (Vd/F) Apparent oral volume of distribution

    Serum Vd/F

    Time frame: Serial blood samples will be collected to determine concentrations of nirogacestat (in serum) on Day 1, Day 6, and Day 17 predose (-30 minutes) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours postdose

  6. To evaluate the Adverse Events in healthy male participants after a single 150 mg dose of nirogacestat administered with and without rabeprazole or famotidine

    Safety assessments will include assessments of all adverse events (AEs) including any serious adverse events (SAEs) and graded using the most current version of the Common Terminology Criteria for Adverse Events CTCAE Version 5.0 condition-specific scale

    Time frame: Baseline through Day 21 and includes the Follow-up Phone Call

  7. Number of Participants with Clinical Laboratory Tests Values Outside the Normal Reference Range

    The laboratory test includes assessment of chemistry, hematology, coagulation, and urinalysis based on Investigator's decision/assessment.

    Time frame: Baseline (Day -1) through Day 21.

  8. To evaluate the vital sign measurements in healthy male participants after a single 150 mg dose of nirogacestat administered with and without rabeprazole or famotidine

    Safety assessments will include assessments of all vital sign measurements of Heart Rate, Blood Pressure, Respirations and Body Temperature

    Time frame: Baseline (Day -1) through Day 21.

  9. To evaluate ECG parameters in healthy male participants after a single 150 mg dose of nirogacestat administered with and without rabeprazole or famotidine

    Safety assessments will include assessments of all electrocardiograms (ECGs) to include heart rate and measures PR, QRS, QT, and QTcF and QT corrected using Bazett's formula (QTcB).

    Time frame: Baseline (Day -1) through Day 21.

  10. To evaluate physical examination findings in healthy male participants after a single 150 mg dose of nirogacestat administered with and without rabeprazole or famotidine

    Safety assessments will include assessments of all physical examination findings to include assessments of the cardiovascular, dermatological, respiratory, gastrointestinal, skin, and neurological systems

    Time frame: Baseline (Day -1) through Day 21.

07

Study locations

1 site
  • Medpace
    Cincinnati, Ohio 45227, United States
08

References and documents

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Nov 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 12, 2025
StartActual
Aug 21, 2025
Primary completionActual
Nov 10, 2025
CompletionActual
Nov 10, 2025
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07171619
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Aug 21, 2025
Primary completion
Nov 10, 2025
Completion
Nov 10, 2025
Last update
May 8, 2026

Study contacts

Mary Beth Brune, MD
principal investigator · Medpace, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nirogacestat · Famotidine · Rabeprazole

Start the discussion